Beta Bionics (BBNX) Current Deferred Revenue (2023 - 2026)

Beta Bionics has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $1.9 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue rose 64.86% year-over-year to $1.9 million; the TTM figure through Jun 2026 stood at $1.9 million (up 64.86% YoY), while the FY2025 annual figure was $1.6 million, up 65.81% from the prior year.
• Current Deferred Revenue came in at $1.9 million for Q2 2026 at Beta Bionics, up from $1.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.9 million in Q2 2026 to a low of $87000.0 in Q4 2023.
• Average Current Deferred Revenue over 4 years is $1.2 million, with a median of $1.2 million recorded in 2025.
• Year-over-year, Current Deferred Revenue soared 979.31% in 2024 and jumped 64.86% in 2026.
• Over 4 years, Current Deferred Revenue stood at $87000.0 in 2023, then soared by 979.31% to $939000.0 in 2024, then jumped by 65.81% to $1.6 million in 2025, then increased by 20.81% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $1.9 million in Q2 2026, $1.7 million in Q1 2026, and $1.6 million in Q4 2025.